Table 1.
Patient demographics
| Characteristic | Placebo | Eplerenone |
|---|---|---|
| n=10 | n=13 | |
| Age (mean±SD), yr | 14.4±2.4 | 15.5±3.0 |
| Sex, n (%) | ||
| Male | 5 (50) | 10 (77) |
| Female | 5 (50) | 3 (23) |
| Graft source, n (%) | ||
| Living related donor | 8 (80) | 10 (77) |
| Deceased donor | 2 (20) | 3 (23) |
| Cause of ESRD, n (%) | ||
| Unknown | 6 (60) | 6 (46) |
| Structural | 3 (30) | 5 (38) |
| Glomerulopathies | 1 (10) | 2 (16) |
| Mo post-transplant, median (25th, 75th percentile) | 11 (8, 34) | 10 (9, 23) |
| Baseline eGFR, ml/min per 1.73 m2 | 80±6 | 86±6 |
| Immunosuppression, n (%) | ||
| Sirolimus | 2 (20) | 2 (15) |
| Calcineurin inhibitor | 8 (80) | 12 (92) |
| Cyclosporine | 1 (13) | 0 (0) |
| Tacrolimus | 7 (88) | 11 (85) |
| Mycophenolate mofetil | 10 (100) | 13 (100) |
| Prednisone | 10 (100) | 12 (92) |
| Tacrolimus trough levels, ng/ml (mean±SD) | ||
| Baseline | 7.0±1.6 | 6.5±1.5 |
| 24 mo | 5.1±1.3 | 5.2±1.7 |
| Mycophenolate mofetil, mg/m2 (mean±SD) | ||
| Baseline | 732±113 | 708±97 |
| 24 mo | 718±68 | 698±125 |
| Prednisone (mg/kg) mean±SD | ||
| Baseline | 0.12±0.01 | 0.12±0.03 |
| 24 mo | 0.11±0.01 | 0.11±0.01 |
| History of acute rejection, n (%) | 7 (70) | 9 (69) |
| CMV risk, n (%) | ||
| Medium (D+/R+) | 10 (100) | 12 (92) |
| High (D+/R−) | 0 (0) | 1 (8) |
| Hospitalization during the study, n (%) | ||
| Positive CMV antigenemia | 1 (10) | 2 (15) |
| Gastroenteritis | 2 (20) | 1 (8) |
| Urinary tract infection | 1 (10) | 2 (15) |
| All | 4 (40) | 5 (38) |
CMV, cytomegalovirus.